Stockscreener 앱 받기
3.90
0.78%
0.03
시간 외 거래:
3.98
0.08
+2.05%
전일 마감가:
$3.87
열려 있는:
$3.88
하루 거래량:
2.85M
Relative Volume:
1.04
시가총액:
$431.21M
수익:
$34.86M
순이익/손실:
$-103.80M
주가수익비율:
-3.2928
EPS:
-1.1844
순현금흐름:
$-96.02M
1주 성능:
+1.30%
1개월 성능:
+23.03%
6개월 성능:
+57.89%
1년 성능:
+140.74%
1일 변동 폭
$3.84
$4.245
1주일 범위
$3.44
$4.245
52주 변동 폭
$1.36
$4.5981
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.90 | 427.90M | 34.86M | -103.80M | -96.02M | -1.1844 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | TD Cowen | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics reports updated cemsidomide data at EHA 2026 - grafa.com
C4 Therapeutics Presents Phase 1 Data at European Hematology Association 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - Investing News Network
C4 Therapeutics presents cemsidomide data at EHA congress - Investing.com UK
C4 Therapeutics presents cemsidomide data at EHA congress By Investing.com - Investing.com Australia
C4 Therapeutics (CCCC) Unveils Phase 1 Trial Insights on Cemsido - GuruFocus
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D - marketscreener.com
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress - TipRanks
C4 Therapeutics posts Phase 1 cemsidomide data and corporate presentation ahead of EHA 2026 - TradingView
C4 Therapeutics (NASDAQ: CCCC) highlights cemsidomide Phase 1 response rates in RRMM - Stock Titan
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - The Manila Times
Heavily pretreated myeloma patients see durable responses on C4 oral therapy - Stock Titan
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Director Anderson (NASDAQ: CCCC) exercises 1,070 options at $2.11 - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics (ABEO) details FDA Pre-IND meeting and 2027 IND goal for ABO-701 - Stock Titan
Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options - Stock Titan
Viking Therapeutics (NASDAQ: VKTX) Chief Medical Officer named insider in Form 3 filing - Stock Titan
Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat - Traders Union
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo Finance
C4 Therapeutics, Inc. (CCCC) reports Q1 loss, lags revenue estimates - MSN
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 'Buy' On Cemsidomide Advancement And Competitor's Positive Readout (CCCC) - Seeking Alpha
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - PR Newswire
C4 Therapeutics' Cemsidomide: A Foundational Treatment Across Multiple Lines Of Multiple Myeloma? - RTTNews
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
C4 Therapeutics (CCCC) upgraded to buy: What does it mean for the stock? - MSN
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Suc - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics (CCCC) Hits 52-Week High Following BMY Trial Success - GuruFocus
CCCC (NASDAQ) insider exercise-and-sale: 9,087 options sold from 29,080 grant - Stock Titan
CCCC: Cemsidomide demonstrates robust late-line efficacy and safety, with global expansion and new combinations planned - TradingView
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):